Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose prourokinase fibrinolysis vs standard dose for STEMI at high altitude
ChiCTR2500106828Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2025
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of recombinant human prourokinase in acute ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Proportion of patients with successful coronary artery recanalization. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on ChiCTR2500106828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106828.